|

A Follow-up Study to Evaluate the Safety of ALLO-ASC-DFU in ALLO-ASC-DFU-302 Clinical Trial

RECRUITINGSponsored by Anterogen Co., Ltd.
Actively Recruiting
SponsorAnterogen Co., Ltd.
Started2023-04-25
Est. completion2025-12-31
Eligibility
Age19 Years – 75 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06141811

Summary

This is a follow-up study to evaluate the safety for the subjects with ALLO-ASC-DFU treatment in phase 3 clinical trial (ALLO-ASC-DFU-302) for 24 months

Eligibility

Age: 19 Years – 75 YearsHealthy volunteers accepted
Inclusion Criteria:

1. Subjects who are treated with ALLO-ASC-DFU sheet or Vehicle sheet in phase 3 clinical trial of ALLO-ASC-DFU-302.
2. Subjects who are able to give written informed consent prior to study start and to comply with the study requirements.

Exclusion Criteria:

1\. Subjects who are considered not suitable for the study by the principal investigator.

Conditions2

DiabetesDiabetic Foot Ulcer

Interventions1

ALLO-ASC-DFU

Browse More Trials

Diabetes trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.